Mean percent PASI improvement with bimekizumab in patients with moderate to severe plaque psoriasis: Pooled results from four phase 3/3b trials. (2021). SKIN The Journal of Cutaneous Medicine, 5(6), s55. https://doi.org/10.25251/skin.5.supp.55